Oxbryta
(Voxelotor)ApprovedSmall molecule
Oxbryta is a small molecule that works as a Hemoglobin Hba Positive Modulator.[2] It is being used across 8 indications, with its most advanced program in Approved.[1]
Oxbryta is one of 243 small molecule programs targeting Kidney Disease. It is currently in Approved.
8
Indications
19
Total Trials
1
Active Trials
242
Competitors
2
FDA Applications
NDA/BLA/ANDA regulatory filings
11
Patents
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
540 competitors in Chronic Kidney Disease
#DrugCompanyPhaseTrials
1Oxbryta
GGlobal Blood Therapeutics
Approved
Aranesp
AmgenPreclinical
Sovaldi
GileadPreclinical
Glucotrol
PfizerPreclinical
Vemlidy
GileadPreclinical
Miochol
BBausch Health Americas, Inc.
Preclinical
Epoetin Beta
RochePreclinical
Baraclude
KKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Preclinical
Viagra
VViatris Specialty LLC
Preclinical
Sodium Valproate
AstraZenecaPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sickle Cell Disease5 trials
9 more indications
Exercise1 trial
Voxelotor Sickle Cell Exercise Study
Completed·—·Phase 4·NCT04581356·14 enrolled
Adult1 trial
Voxelotor for Improving Oxygen Saturation in Adults
Terminated·—·Phase 2·NCT05289570·3 enrolled
Anemia1 trial
Treatment1 trial
Regulatory
FDA Approval Timeline[4]
Dec 17, 2021
OXBRYTA
NDA NDA216157
Oct 14, 2022
OXBRYTA
NDA NDA213137
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Voxelotor. EMBL-EBI & Wellcome Sanger Institute.
- [4]
- [5]
- [6]
Details
Drug Info
Quick Facts
- Mechanism of Action
- Hemoglobin Hba Positive Modulator[2]
- Modality
- Small molecule[2]
- Highest Phase
- Approved[1]
- Company
- GGlobal Blood Therapeutics